Universität zu Köln

Journal Article

Armand, Philippe, Murawski, Niels, Molin, Daniel, Zain, Jasmine, Eichhorst, Barbara, Gulbas, Zafer, Hawkes, Eliza A., Pagel, John M., Phillips, Tycel ORCID: 0000-0003-2143-9672, Ribrag, Vincent, Svoboda, Jakub, Stathis, Anastasios, Chatterjee, Arkendu, Orlowski, Robert, Marinello, Patricia and Christian, Beth (2020). Pembrolizumab in relapsed or refractory Richter syndrome. Br. J. Haematol., 190 (2). S. E117 - 4. HOBOKEN: WILEY. ISSN 1365-2141

Awan, Farrukh ORCID: 0000-0003-1813-9812, Jaeger, Ulrich, Rifkin, Robert, Thirman, Michael J., Byrd, John C., Hallek, Michael, Stromatt, Scott and Pagel, John M. (2012). Phase 1b Study of TRU-016, an Anti-CD37 SMIP (TM) Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Coutre, Steven E., Furman, Richard R., Sharman, Jeff Porter, Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert Aaron, Ervin, Thomas J., Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew, Kim, Yeonhee, Jahn, Thomas Michael, O'Brien, Susan Mary and Hallek, Michael J. (2014). Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian ORCID: 0000-0001-6724-290X, Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D., Hallek, Michael and O'Brien, Susan M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 370 (11). S. 997 - 1008. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Hallek, Michael, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D. and O'Brien, Susan M. (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 122 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Ghia, Paolo, O'Brien, Susan Mary, Hillmen, Peter, Furman, Richard R., Coutre, Steven E., Sharman, Jeff Porter, Cheson, Bruce D., Pagel, John M., Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Eradat, Herbert Aaron, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Hallek, Michael J., Coiffier, Bertrand, Pettitt, Andrew, Ye, Wei, Jahn, Thomas Michael and Wagner, Lynne I. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Pagel, John M., Coutre, Steven E., Furman, Richard R., Sharman, Jeff P., Cheson, Bruce D., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Eradat, Herbert A., Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew, Li, Xiaoming, Jahn, Thomas M., O'Brien, Susan M. and Hallek, Michael J. (2015). Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia. Clin. Lymphoma Myeloma Leuk., 15. S. S201 - 2. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Robak, Tadeusz, Hellman, Andrzej, Loscertales, Javier, Lech-Maranda, Ewa ORCID: 0000-0001-9592-0851, Pagel, John M., Mato, Anthony R., Byrd, John C., Awan, Farrukh ORCID: 0000-0003-1813-9812, Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Stromatt, Scott and Kloczko, Janusz (2014). Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR (TM) Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Robak, Tadeusz, Hellmann, Andrzej, Kloczko, Janusz, Loscertales, Javier, Lech-Maranda, Ewa ORCID: 0000-0001-9592-0851, Pagel, John M., Mato, Anthony, Byrd, John C., Awan, Farrukh T., Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Eisenfeld, Amy J., Stromatt, Scott C. and Jaeger, Ulrich (2017). Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br. J. Haematol., 176 (4). S. 618 - 629. HOBOKEN: WILEY. ISSN 1365-2141

Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M. and Stilgenbauer, Stephan (2019). Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J. Clin. Oncol., 37 (16). S. 1391 - 1405. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Hallek, Michael, Coiffier, Bertrand, O'Brien, Susan, Tausch, Eugen, Kreuzer, Karl-Anton, Jiang, Wendy, Lazarov, Mirella, Li, Daniel, Jahn, Thomas M. and Stilgenbauer, Stephan (2014). Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG (R)) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Sharman, Jeff Porter, Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline Claudia, Zelenetz, Andrew David, Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Hallek, Michael J., Coiffier, Bertrand, O'Brien, Susan Mary, Tausch, Eugen, Kreuzer, Karl A., Jiang, Wendy, Jahn, Thomas Michael, Lazarov, Mirella and Stilgenbauer, Stephan (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755